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Introduction
Angioid streaks are irregular dark red or brownish
lines radiating from the optic nerve head. They repre-
sent breaks or dehiscences in thickened and calcified
Bruch’s membrane and are associated with systemic
diseases such as pseudoxanthoma elasticum.1 Secondary
development of choroidal neovascularization (CNV)
is the most important and frequent complication. The
natural history and visual prognosis is usually poor
due to macular involvement and central vision loss.2
Laser photocoagulation has limited success and high
recurrence rate in treating CNV secondary to angioid
streaks.2 The long-term efficacy of photodynamic ther-
apy (PDT) for angioid streaks and CNV remains under
evaluation. Until recently, there were rare reports of ef-
fective therapy for CNV associated with angioid streaks
in the literature.
Herein, we report our experience with managing 
a case of bilateral CNV in angioid streaks. Prior
transpupillary thermotherapy and intravitreal injection
of triamcinolone did not prevent enlargement of CNV
and a final disciform scar formation in the left eye of our
patient. Thereafter, intravitreal injection of bevacizumab
(Avastin; Genentech Inc., South San Francisco, CA,
USA) was used as a salvage treatment in his right 
eye, and CNV completely regressed, with rapid vision
improvement. There was no recurrent CNV during
18 months of follow-up. To the best of our knowledge,
this is the longest follow-up period for this treatment
modality ever reported.
Case Report
An 82-year-old male with a medical history of hyper-
tension and old myocardial infarction came to our clinic
due to blurred vision of the left eye for 1 month. Upon
examination, best-corrected visual acuity (BCVA) was
20/32 in the right eye and 20/100 in the left eye.
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Bevacizumab for CNV in angioid streaks
The anterior segments and intraocular pressure were
normal in both eyes. Fundus examination showed bilat-
eral angioid streaks, extrafoveal CNV membrane with
macular hemorrhage and edema in the left eye (Figure
1A). Fluorescein angiography (FA) revealed hyperfluo-
rescence corresponding to angioid streaks and leakage
of extrafoveal CNV in the left eye (Figure 1B). The
greatest linear dimension (GLD) of CNV, including
CNV leakage area and blood-blocked hypofluorescence
area, was 1,600μm.
Triamcinolone acetonide (2 mg) was intravitreally
injected in the left eye, and it consequently diminished
macular edema and hemorrhage within 1 month after
the injection. However, extended CNV membrane with
increased marginal hemorrhage to 2,600μm in GLD
was noted in the left eye 2 months later (Figures 1C and
1D). The patient chose to undergo transpupillary ther-
motherapy (TTT) (550mW in energy, 3.0mm spot size,
60 seconds of exposure time) rather than PDT for treat-
ment of his left eye due to financial considerations.
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Figure 1. Progression of choroidal neovascularization (CNV) asso-
ciated with angioid streaks in the left eye. (A) At initial presenta-
tion, extrafoveal CNV membrane (arrow) with macular hemorrhage
and macular edema secondary to angioid streaks were noted.
(B) Fluorescein angiography (FA) showed hyperfluorescence cor-
responding to the angioid streaks and dye leakage of CNV (arrow).
(C) Three months later, extended CNV membrane with increased
marginal hemorrhage (arrow) was observed. (D) FA revealed in-
creased hyperfluorescent dye leakage from extended CNV mem-
brane and blocked hypofluorescence area from marginal retinal
hemorrhage. (E) One year after transpupillary thermotherapy, there
was disciform scar formation, and best-corrected visual acuity
remained at 20/200.
During 1 year of follow-up after TTT, macular
disciform scar formation occurred and BCVA remained
at 20/200 in his left eye (Figure 1E). Meanwhile,
extrafoveal CNV with retinal thickening and cystic
edema were still noted on optical coherence tomog-
raphy (OCT) (Figure 2A). In addition, the patient
suffered from metamorphopsia with BCVA of 20/40 
in his right eye, and fundoscopy disclosed juxtafoveal
hemorrhage and macular edema in his right eye
(Figure 3A). FA showed active dye leakage from the
juxtafoveal CNV, measuring 1,200μm in GLD
(Figure 3B), and OCT showed juxtafoveal CNV and
retinal edema in his right eye (Figure 2B).
After explaining the therapeutic options, the off-
label use of bevacizumab (Avastin; Genentech Inc.)
and its potential risks and benefits were discussed
with the patient. He signed a comprehensive consent
form. The patient was treated with an off-label intra-
vitreal injection of bevacizumab 2.5 mg/0.1 mL into
his right eye. Two weeks after the injection, there was
marked decrease of juxtafoveal hemorrhage on fun-
dus examination (Figure 3C), and FA demonstrated
obvious regression of CNV with dye staining only in
his right eye (Figure 3D). There was also apparent
resolution of juxtafoveal CNV and retinal edema on
OCT (Figure 2C). The BCVA of the right eye im-
proved to 20/25 1 month after the injection. The
patient underwent another 2 repeat intravitreal injec-
tions of bevacizumab 2.5 mg/0.1 mL in the right eye
at 1-month intervals. The BCVA in his right eye was
preserved at 20/25, without recurrent CNV lesion or
new hemorrhage, during 18 months of follow-up.
Discussion
CNV has been reported to occur from discontinuities
or breaks in thickened and calcified Bruch’s mem-
brane in 70–86% of patients with angioid streaks. The
visual prognosis of such lesions is poor because the
natural history is aggressive and most have macular in-
volvement.2 Until recently, therapy for CNV in patients
with angioid streaks remained a great challenge to
ophthalmologists.
Laser photocoagulation may close the CNV and help
stabilize visual acuity or slow visual loss, but with a
very high frequency of recurrence.2 TTT has also been
used to treat CNV in patients with angioid streaks
who had enlargement of the lesion and decrease in
visual acuity.3 The authors commented that TTT did
not appear to alter the course of the disease and the
visual prognosis was usually poor.3 Our case had simi-
lar results following TTT in the left eye. Verteporfin
PDT was recently used as an alternative therapy for
CNV secondary to angioid streaks, but its benefits are
still under evaluation. Browning et al4 showed that
PDT appeared to limit visual loss through the first 12
months of follow-up, and Karacorlu et al5 described a
short-term cessation or decrease of fluorescein leak-
age from CNV after PDT treatment. However, over a
longer follow-up period, PDT did not seem to pre-
vent disease progression, CNV growth and vision
loss.6 We have recently presented increased and per-
sistent subretinal hemorrhage with a final disciform
scar formation after PDT for CNV secondary to angioid
streaks.7 The visual prognosis was poor despite retreat-
ments with PDT.
Bevacizumab is a humanized monoclonal antibody
to vascular endothelial growth factor (VEGF) designed
for intravascular administration, and is approved by
the FDA for the treatment of metastatic colorectal
cancer.8 Improvements in visual acuity, FA and OCT
with intravitreal injection of bevacizumab to treat
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Figure 2. Choroidal neovascularization (CNV) associated with angioid
streaks shown by optical coherence tomography (OCT). (A) In the
left eye, extrafoveal CNV with retinal thickening and cystic edema
(arrows) were noted 1 year after transpupillary thermotherapy. The
central macular thickness on OCT was 317μm. There was macular
disciform scar formation and best-corrected visual acuity (BCVA)
remained at 20/200. (B) At initial presentation of the right eye,
juxtafoveal CNV (arrow) and intraretinal edema (arrowhead) were
noted on OCT. (C) Two weeks after intravitreal injection of beva-
cizumab into the right eye, there was regression of CNV and reso-
lution of retinal edema on OCT. BCVA improved from 20/40 to
20/25 1 month after the injection.
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neovascular age-related macular degeneration (AMD)
have been reported by Rosenfeld et al.9 Based on this
report, we hypothesized that this potent VEGF inhibitor
might suppress CNV secondary to angioid streaks.
Bevacizumab may be a promising pharmacologic treat-
ment in this field, but has rarely been discussed.10,11
In the left eye of the present case, TTT and intra-
vitreal triamcinolone did not prevent the angiogenesis
and enlargement of CNV, but produced disciform scar
and poor visual outcome. Owing to the patient’s re-
fusal to receive PDT, we decided to perform an off-
label intravitreal injection of bevacizumab into his right
eye as a salvage treatment. The patient rapidly and
favorably improved in visual acuity and FA outcome,
and the retinal structures normalized on OCT exami-
nation. We thought that these favorable functional and
anatomic results might be due to the combined anti-
leakage and anti-angiogenesis effect of bevacizumab
without inducing any chorioretinal tissue damage.
These improvements were maintained without recur-
rence of CNV after 2 additional bevacizumab monthly
injections. Our results from using this anti-VEGF agent
in angioid streaks have shown that it is able to arrest the
progression of CNV with long-term quiescence follow-
ing 3 injections. This might imply that the pathogenic
activity of CNV secondary to angioid streaks is more
similar to that of pathologic myopia than that of AMD.
Longer follow-up and prospective studies are necessary
for further evaluation of the long-term therapeutic
effects and optimal injection frequency.
In conclusion, we presented a patient with bilat-
eral CNV in angioid streaks. TTT and intravitreal tri-
amcinolone did not prevent enlargement of CNV and
disciform scar formation in prior left eye treatment.
In contrast, after intravitreal injection of bevacizumab
in the right eye, CNV completely regressed, with vision
improvement over 18 months of follow-up. The short-
term therapeutic effect was satisfactory in both visual
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Figure 3. Regression of choroidal neovascularization (CNV) associated with angioid streaks after intravitreal injection of bevacizumab in
the right eye. (A) Fundus photography revealed angioid streaks and juxtafoveal CNV with new retinal hemorrhage (arrow). (B) Active dye
leakage of juxtafoveal CNV (arrow) and macular edema were noted on fluorescein angiography (FA). (C) Two weeks after treatment with
intravitreal injection of bevacizumab, there was rapid and marked decrease in juxtafoveal hemorrhage. (D) There was obvious regression
of CNV leakage, with dye staining only noted on FA.
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and anatomic outcomes. Since no ideal treatment has
been available for this disease with an aggressive course,
intravitreal injection of bevacizumab appears to be
promisingly effective in treating such patients.
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